Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants
Public ClinicalTrials.gov record NCT04825223. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants
Study identification
- NCT ID
- NCT04825223
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Enrollment
- 576 participants
Conditions and interventions
Conditions
Interventions
- Multicomponent Meningococcal B Vaccine Drug
- Meningococcal Group B Vaccine MenB Drug
- Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed) Drug
- Placebo Drug
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine Drug
Drug
Eligibility (public fields only)
- Age range
- 42 Days to 50 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2021
- Primary completion
- Jul 21, 2022
- Completion
- Jul 21, 2022
- Last update posted
- Oct 9, 2025
2021 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lakeview Clinical Research Site Number : 8400029 | Guntersville | Alabama | 35976-2206 | — |
| California Research Foundation Site Number : 8400005 | San Diego | California | 92123-1881 | — |
| PAS Research Site Number : 8400032 | Tampa | Florida | 33613 | — |
| Brengle Family Medicine Site Number : 8400044 | Indianapolis | Indiana | 46260 | — |
| AMR El Dorado Site Number : 8400018 | El Dorado | Kansas | 67042 | — |
| Alliance for Multispecialty Research LLC Site Number : 8400013 | Wichita | Kansas | 67205 | — |
| Prime Global Research, Inc. Site Number : 8400043 | The Bronx | New York | 10456 | — |
| The Research Center of the Upstate Site Number : 8400008 | Greenville | South Carolina | 29607 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04825223, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2025 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04825223 live on ClinicalTrials.gov.